Lupin Limited has announced the appointment of Mr. Brian Savage as President and Chief Legal Officer, effective October 22, 2026. In this senior management role, Mr. Savage will be responsible for overseeing the company’s Global Legal, Compliance, and Intellectual Property functions. He brings extensive legal leadership experience from the global pharmaceutical industry, including his previous roles at Teva Pharmaceuticals.
Lupin Appoints New Senior Management Personnel
Lupin Limited is pleased to announce the appointment of Mr. Brian Savage to its senior management team. Effective October 22, 2026, Mr. Savage will assume the role of President, Chief Legal Officer. This strategic appointment underscores Lupin’s commitment to strengthening its leadership in critical functional areas.
Key Responsibilities and Background
As President, Chief Legal Officer, Mr. Savage will lead and oversee the company’s comprehensive Global Legal, Compliance, and Intellectual Property operations. His extensive experience in the pharmaceutical sector is expected to bring significant value to these functions. Prior to joining Lupin, Mr. Savage held senior leadership positions at Teva Pharmaceuticals, most recently serving as Executive Vice President and Interim Global Chief Legal Officer. He also has prior experience practicing law at Dechert LLP and holds a Juris Doctor (J.D.) degree from Yale Law School.
Details of Appointment
The appointment is for a full-time employment term. The company has provided details as required under Regulation 30 of the SEBI Listing Regulations. The specific details of the appointment, including Mr. Savage’s profile and the responsibilities associated with his new role, are outlined in Annexure I of the disclosure.
Source: BSE
